Sartorius Stedim Biotech S.A.

Total Valuation

Sartorius Stedim Biotech S.A. carries a market capitalization of 23.74B, placing it among publicly traded companies globally. Its enterprise value stands at 19.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sartorius Stedim Biotech S.A. currently has 97.29M shares outstanding.

Valuation Ratios

Sartorius Stedim Biotech S.A. trades at a trailing price-to-earnings ratio of 93.62. The price-to-sales ratio is 7.37, and the price-to-book ratio stands at 4.02.

Enterprise Valuation

On an enterprise value basis, Sartorius Stedim Biotech S.A. trades at an EV/EBITDA multiple of 43.90 and an EV/FCF ratio of 21.35. The EV/Sales ratio of 8.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 43.90 provides insight into valuation relative to core operating earnings.

Financial Position

Sartorius Stedim Biotech S.A. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.57, indicating elevated leverage, while an interest coverage ratio of 5.88 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Sartorius Stedim Biotech S.A. posts a return on equity of 4.40 and a return on invested capital of 4.47.

Taxes

Over the trailing twelve months, Sartorius Stedim Biotech S.A. has paid 94.40M in income taxes, reflecting an effective tax rate of 29.17.

Stock Price Statistics

Sartorius Stedim Biotech S.A.'s stock has gained approximately 11.92661% over the past 52 weeks. The 50-day moving average sits at 217.14, while the 200-day moving average is 212.21.

Income Statement

Over the trailing twelve months, Sartorius Stedim Biotech S.A. generated 2.30B in revenue and converted that into 181.10M in net income, yielding earnings per share of 2.37. EBITDA reached 437.70M, while operating income came in at 437.70M.

Balance Sheet

Sartorius Stedim Biotech S.A. holds 232.80M in cash and equivalents against 2.40B in total debt, resulting in a net debt position of 2.03B. Total book value stands at 4.24B, with working capital of 186.20M providing operational flexibility.

Cash Flow

Sartorius Stedim Biotech S.A. produced 587.70M in operating cash flow over the past twelve months. After subtracting -259.50M in capital expenditures, free cash flow totaled 328.20M - equivalent to 3.39 per share.

Margins

Sartorius Stedim Biotech S.A. operates with a gross margin of 44.41, reflecting its pricing power and cost economics. The operating margin of 19.04 and net profit margin of 7.88 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Sartorius Stedim Biotech S.A.'s most recent stock split took place on May 6, 2016 with a 1:6 split ratio.

Scores

Sartorius Stedim Biotech S.A. posts an Altman Z-Score of 5.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.